Full-Time

Director – Investor Relations and Corporate Communications

Confirmed live in the last 24 hours

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Senior

Remote in USA

Category
Corporate Finance
Finance & Banking
Required Skills
Communications
Requirements
  • Bachelor’s degree in Finance, Business Administration, Science, Communications or related field
  • 10+ years of experience in investor relations, equity research, or related roles, preferably within the pharmaceutical or biotech industry.
  • Strong understanding of healthcare investment principles and experience in analyzing and articulating both financial and clinical results for an investor audience
  • Excellent communication and presentation skills, with the ability to convey complex information clearly and persuasively.
  • Proven ability to build and maintain relationships with investors, analysts, and other stakeholders.
  • Strong analytical skills, with the ability to interpret market trends to inform investor relations strategy.
  • Experience with financial reporting, SEC filings, and compliance with regulatory requirements.
  • Proficiency in financial modeling, analysis, and investor relations software.
  • Experience working in a public company, with a strong understanding of SEC regulations and investor communication requirements.
  • Experience with media relations and public relations is a plus.
Responsibilities
  • Develop and execute a comprehensive investor relations strategy for the US market that aligns with Telix’s global IR strategy goals and enhances its reputation in the investment community.
  • Serve as a primary point of contact for US and European investors, analysts and other stakeholders, providing accurate and timely information about Telix’s financial performance, strategy, and outlook.
  • Prepare and manage the company’s quarterly earnings calls, including the preparation of press releases, presentations, and Q&A sessions.
  • Organize and participate in investor meetings, roadshows, and conferences to maintain strong relationships with existing investors and attract new ones.
  • Monitor and analyze consensus, market trends, investor sentiment, and the company’s stock performance, providing insights and recommendations to SVP IR and senior management.
  • Provide feedback on investor perceptions and concerns and help shape the company’s strategy and communications in response.
  • Prepare reports to the executive team and board of directors on investor relations activities, market trends, and stock performance.
  • Ensure compliance with all regulatory requirements related to financial reporting, disclosure, and investor communications.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products aim to help healthcare providers make better treatment decisions and offer personalized therapies for conditions that lack effective treatments. The company focuses on areas like prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a strong global supply chain to ensure its products are available to healthcare institutions and professionals. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The goal of Telix Pharmaceuticals is to improve the quality of life for patients by providing advanced diagnostic and therapeutic solutions.

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

18%

1 year growth

43%

2 year growth

106%
Simplify Jobs

Simplify's Take

What believers are saying

  • Telix's acquisition of RLS enhances its North American manufacturing and distribution capabilities.
  • The NDA submission for TLX101-CDx could address unmet needs in glioma diagnosis.
  • Reorganization into four business units aligns with strategic priorities and optimizes operations.

What critics are saying

  • Increased competition from companies like Lantheus in the theranostic agents market.
  • Retirement of co-founder Andreas Kluge may lead to strategic shifts or instability.
  • The $250 million RLS acquisition could strain financial resources if integration falters.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates diagnostics and therapy, offering personalized treatment for complex diseases.
  • Telix's global supply chain ensures product availability and delivery worldwide.

Help us improve and share your feedback! Did you find this helpful?